ATE264859T1 - Neue adenosin-monophosphat-deaminase-inhibitoren - Google Patents

Neue adenosin-monophosphat-deaminase-inhibitoren

Info

Publication number
ATE264859T1
ATE264859T1 AT94907992T AT94907992T ATE264859T1 AT E264859 T1 ATE264859 T1 AT E264859T1 AT 94907992 T AT94907992 T AT 94907992T AT 94907992 T AT94907992 T AT 94907992T AT E264859 T1 ATE264859 T1 AT E264859T1
Authority
AT
Austria
Prior art keywords
deeaminase
inhibitors
adenosine monophosphate
new adenosine
compounds
Prior art date
Application number
AT94907992T
Other languages
English (en)
Inventor
Mark David Erion
Brett Carder Bookser
Srinivas Rao Kasibhatla
Harry Edward Gruber
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of ATE264859T1 publication Critical patent/ATE264859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Information Transfer Systems (AREA)
AT94907992T 1993-02-03 1994-02-03 Neue adenosin-monophosphat-deaminase-inhibitoren ATE264859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1284193A 1993-02-03 1993-02-03
PCT/US1994/001342 WO1994018200A1 (en) 1993-02-03 1994-02-03 Novel inhibitors of adenosine monophosphate deaminase

Publications (1)

Publication Number Publication Date
ATE264859T1 true ATE264859T1 (de) 2004-05-15

Family

ID=21756974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907992T ATE264859T1 (de) 1993-02-03 1994-02-03 Neue adenosin-monophosphat-deaminase-inhibitoren

Country Status (10)

Country Link
US (1) US5731432A (de)
EP (1) EP0683781B1 (de)
JP (1) JP3940810B2 (de)
AT (1) ATE264859T1 (de)
AU (1) AU6134994A (de)
CA (1) CA2154577C (de)
DE (1) DE69433722D1 (de)
IL (1) IL108524A0 (de)
MX (1) MX9400874A (de)
WO (1) WO1994018200A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
ES2182847T3 (es) * 1993-09-29 2003-03-16 Nabi Nucleosidos y nucleotidos de anillo expandido.
EP1003469A2 (de) * 1996-02-21 2000-05-31 Givaudan-Roure (International) S.A. Vorläufer von duftstoffen
AU8438798A (en) 1997-06-16 1999-01-04 Janssen Pharmaceutica N.V. Use of draflazine-analogues for treating pain
DE19912636A1 (de) * 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020086835A1 (en) * 2000-05-22 2002-07-04 Law William R. Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
GB0030424D0 (en) * 2000-12-13 2001-01-24 Pfizer Ltd Crystal structure
WO2003051314A2 (en) * 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US7386492B2 (en) * 2002-01-15 2008-06-10 Clear Channel Communications, Inc. Inventory and revenue maximization method and system
MX2007012045A (es) 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102007005329A1 (de) * 2007-01-29 2008-07-31 Eberhard-Karls-Universität Tübingen Universitätsklinikum Mittel zur Erythrozytenprotektion
JP5591245B2 (ja) * 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物
US20100261666A1 (en) * 2009-04-14 2010-10-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of myocardial dysfunction associated with sirs or sepsis
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US20150031712A1 (en) 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
EA201890014A1 (ru) 2015-06-08 2018-07-31 О.Д. Окьюлар Дискавери Лтд. Терапевтические композиции, содержащие дипиридамол, наборы для лечения, содержащие эти композиции, и способы их производства

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935505A (en) * 1983-05-03 1990-06-19 Townsend Leroy B Novel azolo [1,3] diazepine-5-ol compounds and their uses
JPS6281387A (ja) * 1985-10-03 1987-04-14 Kitasato Inst:The 新規化合物ｏｍ−３２２３およびその製造法
WO1989008658A1 (en) * 1988-03-16 1989-09-21 Scripps Clinic And Research Foundation Substituted adenine derivatives useful as therapeutic agents
ES2052172T3 (es) * 1989-03-23 1994-07-01 Pfizer Agentes antialergicos basados en diazepina.
GB8911029D0 (en) * 1989-05-13 1989-06-28 Schering Agrochemicals Ltd Herbicide
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
AU6297294A (en) * 1993-02-03 1994-08-29 Gensia, Inc. Adenosine deaminase inhibitor therapies

Also Published As

Publication number Publication date
EP0683781B1 (de) 2004-04-21
WO1994018200A1 (en) 1994-08-18
CA2154577C (en) 2005-08-02
JPH08506344A (ja) 1996-07-09
JP3940810B2 (ja) 2007-07-04
CA2154577A1 (en) 1994-08-18
US5731432A (en) 1998-03-24
EP0683781A4 (de) 1997-05-28
DE69433722D1 (de) 2004-05-27
EP0683781A1 (de) 1995-11-29
MX9400874A (es) 1994-08-31
AU6134994A (en) 1994-08-29
IL108524A0 (en) 1994-05-30

Similar Documents

Publication Publication Date Title
ATE264859T1 (de) Neue adenosin-monophosphat-deaminase-inhibitoren
MX9200294A (es) Inhibidores de cinasa de adenosina
ATE279921T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
MX9700557A (es) Dihidrobenzofuranos.
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
PL338339A1 (en) Novel derivatives of tetrazole
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
MY129445A (en) Compositions for treating inflammatory response
ATE317912T1 (de) Verfahren zur herstellung von beta-lactamen
DE3369980D1 (en) Disubstituted proline derivatives, process for their preparation and their use
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
NO20011946L (no) Mangansammensetninger og fremgangsmåter for MRI
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
MX9605072A (es) Dispositivo dispensador para pretratamiento.
NZ324615A (en) Method for treating autism using olanzapine
ES2100274T3 (es) Nuevos 2-sacarinilmetil y 4,5,6,7-tetrahidro-2-sacarinilmetil fosfatos, fosfonatos y fosfinatos utiles como inhibidores de enzimas proteoliticos y composiciones y metodos de empleo de los mismos.
ES2040750T3 (es) Un procedimiento para la preparacion de un derivado de isoquinolinol.
SE8400118D0 (sv) Substituted carboxy-thiazolo(3,2-a)pyrimidine derivatives and process for their preparation
DE69531627D1 (de) Humane hypertrophe chrondrozyten zelllinien
BG105624A (en) Process for preparing n6-substituted deaza-adenosine derivatives
DE69626010D1 (de) Verwendung von tropolon derivate zur hemmung des inositmono phosphatase
GEP19970991B (en) Method for Decay of Tumor Cells with Mammalia and Pharmacentical Composition for this Purpose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties